I'rom Group Co., Ltd. Reports Consolidated Earnings Results for the Nine Months Ended December 2019; Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 2020; Provides Year End Dividend for the Year Ending March 31, 2020
February 05, 2020
Share
I'rom Group Co., Ltd. reported consolidated earnings results for the nine months ended December 2019. Net sales were JPY 7,278 million compared to JPY 7,954 million a year ago. Operating income was JPY 581 million compared to JPY 875 million a year ago. Ordinary income was JPY 697 million compared to JPY 858 million a year ago. Net income attributable to owners of parent was JPY 518 million compared to JPY 687 million a year ago. Net income per share was at JPY 44.52 against JPY 58.86 per share reported last year. Diluted net income per share was JPY 43.76 against JPY 56.76 per share reported last year.
The company provided earnings forecast for the fiscal year ending March 2020, on consolidated basis, the company expects net sales to be JPY 13,000 million, operating income to be JPY 1,300 million, ordinary income to be JPY 1,300 million, net income attributable to owners of parent to be JPY 1,000 million and net income per share to be JPY 85.79.
The company provided year end dividend forecast for the year ending March 2020. For the period, the company expects to pay year end dividend of JPY 20.00 per share. The this bring the total dividend for the year at JPY 40.00 per share.
I'rom Group Co.,Ltd. is engaged in medical fields such as regenerative medicine and gene discovery. The Company operates through four business segments. The SMO segment provides support services for contracting or substituting a part of the work related to conducting clinical trials from the conducting medical institution. The CRO segment provides all or part of clinical trial operations from pharmaceutical companies and others. The Advanced Medicinal Treatment segment is engaged in the development of gene therapy products, the development, manufacture and sale of products in the field of regenerative medicine based on iPS cells related technologies, as well as the provision of contract manufacture services. The Medical Support segment provides general and comprehensive support for medical business management, such as setting up and renting clinic malls, selling products and related services. The Company also provides business utilizing IT infrastructure.
I'rom Group Co., Ltd. Reports Consolidated Earnings Results for the Nine Months Ended December 2019; Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 2020; Provides Year End Dividend for the Year Ending March 31, 2020